Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 34 articles: HTML format

Single Articles

October 2024
1. ROMESSER PB, Cercek A
   Optimizing Rectal Cancer Treatment: A Path Towards Personalization.
   Ann Oncol. 2024;35:831-835.
   PubMed    
   
   
   
2. CONROY T, Castan F, Etienne PL, Rio E, et al
   Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
   Ann Oncol. 2024;35:873-881.
   PubMed     Abstract available
   
   
   
3. LIN ZY, Zhang P, Chi P, Xiao Y, et al
   Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.
   Ann Oncol. 2024;35:882-891.
   PubMed     Abstract available
   
   
   August 2024
4. CIARDIELLO D, Bielo LB, Napolitano S, Martinelli E, et al
   Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
   Ann Oncol. 2024 Aug 28:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334
   PubMed     Abstract available
   
   
   
5. ROS J, Matito J, Villacampa G, Comas R, et al
   Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552].
   Ann Oncol. 2024 Aug 12:S0923-7534(23)00796-2. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   July 2024
6. BIONDO S, Frago R, Kreisler E
   Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
   Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024.
   PubMed    
   
   
   
7. CECCHINI M, Sundar R
   Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta (POLE/POLD1)-altered colorectal cancer.
   Ann Oncol. 2024;35:582-584.
   PubMed    
   
   
   June 2024
8. VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al
   Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
   Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   May 2024
9. AMBROSINI M, Rousseau B, Manca P, Artz O, et al
   Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
   Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
10. BRENNER H, Niedermaier T, Hoffmeister M
    Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
    Ann Oncol. 2024;35:476-477.
    PubMed    
    
    
    April 2024
11. KELSEN D, Ben-Aharon I, Gordon N
    Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
    Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    February 2024
12. LASKAR RS, Qu C, Huyghe JR, Harrison T, et al
    Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
    Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    January 2024
13. SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al
    European cancer mortality predictions for the year 2024 with focus on colorectal cancer.
    Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    November 2023
14. HENRIKSEN TV, Demuth C, Frydendahl A, Nors J, et al
    Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort.
    Ann Oncol. 2023 Nov 20:S0923-7534(23)05073-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
15. CERVANTES A, Martinelli E
    Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline.
    Ann Oncol. 2023 Nov 7:S0923-7534(23)04335-1. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
16. DIENSTMANN R
    Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials.
    Ann Oncol. 2023;34:962-963.
    PubMed    
    
    
    October 2023
17. ROS J, Vivancos A, Tabernero J, Elez E, et al
    Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04326-0. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
18. BESSA X, Vidal J J, Balboa JC, Marquez C, et al
    High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer.
    Ann Oncol. 2023 Oct 5:S0923-7534(23)04010-3. doi: 10.1016/j.annonc.2023.09.3113.
    PubMed     Abstract available
    
    
    August 2023
19. TAIEB J, Sinicrope FA, Pederson L, Lonardi S, et al
    Different prognostic values of KRAS exon 2 sub-mutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials.
    Ann Oncol. 2023 Aug 22:S0923-7534(23)00804-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    June 2023
20. RATOVOMANANA T, Nicolle R, Cohen R, Diehl A, et al
    Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability.
    Ann Oncol. 2023 Jun 1:S0923-7534(23)00695-6. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    April 2023
21. SERRA-ARACIL X, Pericay C
    Reply to the Letter to the Editor 'The role of chemoradiotherapy in organ preservation for rectal cancer' by L. Xie, Q. Chen, and J. Zhu.
    Ann Oncol. 2023;34:440-442.
    PubMed    
    
    
    
22. DE WILT JHW, Bach SP
    Is it time for a paradigm shift in early rectal cancer treatment?
    Ann Oncol. 2023;34:336-338.
    PubMed    
    
    
    
23. XIE L, Chen Q, Zhu J
    The role of chemoradiotherapy in organ preservation for rectal cancer.
    Ann Oncol. 2023;34:440.
    PubMed    
    
    
    March 2023
24. ROS J, Matito J, Villacampa G, Comas R, et al
    Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ann Oncol. 2023 Mar 13:S0923-7534(23)00112-6. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    January 2023
25. SERRA-ARACIL X, Pericay C, Badia-Closa J, Golda T, et al
    Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
    Ann Oncol. 2023;34:78-90.
    PubMed     Abstract available
    
    
    November 2022
26. SABERZADEH-ARDESTANI B, Foster NR, Lee HE, Shi Q, et al
    Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
    Ann Oncol. 2022;33:1159-1167.
    PubMed     Abstract available
    
    
    October 2022
27. CERVANTES A, Adam R, Rosello S, Arnold D, et al
    Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04192.
    PubMed    
    
    
    September 2022
28. MORENO V, Salazar R, Gruber SB
    The prognostic value of TILs in stage III colon cancer must consider sidedness.
    Ann Oncol. 2022 Sep 16. pii: S0923-7534(22)04146.
    PubMed    
    
    
    August 2022
29. GLYNNE-JONES R, Harrison M
    Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?
    Ann Oncol. 2022;33:745-746.
    PubMed    
    
    
    
30. JIMENEZ-FONSECA P, Salazar R, Valenti V, Msaouel P, et al
    Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.
    Ann Oncol. 2022;33:786-793.
    PubMed     Abstract available
    
    
    June 2022
31. ANDRE T, Lonardi S, Wong KYM, Lenz HJ, et al
    Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01737.
    PubMed     Abstract available
    
    
    
32. CICCOLINI J, Milano G
    Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.
    Ann Oncol. 2022 Jun 16. pii: S0923-7534(22)01729.
    PubMed    
    
    
    March 2022
33. BASILE D, Broudin C, Emile JF, Falcoz A, et al
    Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00379.
    PubMed     Abstract available
    
    
    
34. DUCREUX M, Kim S, Borg C
    Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus.
    Ann Oncol. 2022;33:349-350.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.